Back to Search Start Over

Overview of the therapeutic potential of piplartine (piperlongumine).

Authors :
Bezerra DP
Pessoa C
de Moraes MO
Saker-Neto N
Silveira ER
Costa-Lotufo LV
Source :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2013 Feb 14; Vol. 48 (3), pp. 453-63. Date of Electronic Publication: 2012 Dec 11.
Publication Year :
2013

Abstract

Piplartine (piperlongumine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone) is a biologically active alkaloid/amide from peppers, as from long pepper (Piper longum L. - Piperaceae). Long pepper is one of the most widely used in Ayurvedic medicine, which is used to treat many diseases, including tumors. The purpose of the current paper is to address to the chemical structure establishment and to systematically survey the published articles and highlight recent advances in the knowledge of the therapeutic potential of piplartine, establishing new goals for future research. The reported pharmacological activities of piplartine include cytotoxic, genotoxic, antitumor, antiangiogenic, antimetastatic, antiplatelet aggregation, antinociceptive, anxiolytic, antidepressant, anti-atherosclerotic, antidiabetic, antibacterial, antifungal, leishmanicidal, trypanocidal, and schistosomicidal activities. Among the multiple pharmacological effects of piplartine, its anticancer property is the most promising. Therefore, the preclinical anticancer potential of piplartine has been extensively investigated, which recently resulted in one patent. This compound is selectively cytotoxic against cancer cells by induction of oxidative stress, induces genotoxicity, as an alternative strategy to killing tumor cells, has excellent oral bioavailability in mice, inhibits tumor growth in mice, and presents only weak systemic toxicity. In summary, we conclude that piplartine is effective for use in cancer therapy and its safety using chronic toxicological studies should be addressed to support the viability of clinical trials.<br /> (Copyright © 2012 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0720
Volume :
48
Issue :
3
Database :
MEDLINE
Journal :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Publication Type :
Academic Journal
Accession number :
23238172
Full Text :
https://doi.org/10.1016/j.ejps.2012.12.003